ArticleInternational journal of radiation oncology, biology, physics2025
Assessing the Relationship Between MR-Based Functional Dose Metrics and Post-Stereotactic Body Radiation Therapy Albumin-Bilirubin Change.
Article in International journal of radiation oncology, biology, physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeThis study aimed to identify predictors of global liver function change measured by albumin-bilirubin (ALBI) score following stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma (HCC). By integrating gadoxetic acid-enhanced magnetic resonance imaging (MRI) uptake and dosimetric data, the goal was to develop functional-based treatment-planning strategies that preserve hepatic function. METHODS AND MATERIALS: Twenty-five patients with HCC enrolled on an institutional review board-approved adaptive SBRT trial had liver dynamic gadoxetic acid-enhanced MRI and blood sample collections before and 1 month after SBRT. Gadoxetic acid uptake rate (k1) maps were quantified for regional hepatic function and coregistered to both 2-Gy equivalent dose and physical dose distributions. Mean or integral-based metrics, dose-volume or function-volume histogram metrics, and function-dose-volume histogram metrics were calculated. These metrics were correlated with percentage ALBI score changes by Spearman rank correlation with Bonferroni correction.
resultsWe found that the greater the sparing of liver with high-hepatic function (k1 intensity), the less the decline of ALBI score post-RT. The threshold for preserving global hepatic function was 10 % of the maximum k1 intensity and 5 Gy EQD2. The integration of regional function (k1) and dosimetric data improved the ability to predict ALBI score changes compared with dosimetric or functional data alone.
conclusionsCombining regional liver function metrics from gadoxetic acid-enhanced MRI with radiation dose provides a robust model for predicting ALBI score changes following SBRT. These findings suggest that there is a potential for functional-based treatment planning to better preserve liver function in patients with HCC undergoing SBRT. Future studies are needed to externally validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.